IONIS PHARMACEUTICALS INC(NASDAQ:IONS) stock News

IONS Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Yahoo Finance - Mentions: MS NVDA

Why Morgan Stanley Upgraded This Biotech Stock to a Buy

11 days ago - By: The Motley Fool

Ionis (IONS) Q2 Revenue Soars 101%

11 days ago - By: Benzinga

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)

12 days ago - By: The Motley Fool

Ionis (IONS) Q2 2025 Earnings Call Transcript

12 days ago - By: Benzinga

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

12 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis reports second quarter 2025 financial results and highlights progress on key programs

17 days ago - By: Ionis Pharmaceuticals, Inc.

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

21 days ago - By: Ionis Pharmaceuticals, Inc.

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

a month ago - By: Ionis Pharmaceuticals, Inc.

Ionis to hold second quarter 2025 financial results webcast

a month ago - By: Yahoo Finance - Mentions: NKE RJF GS HAS ...

Nike upgraded, Sportradar initiated: Wall Street's top analyst calls

2 months ago - By: Biogen Inc. - Mentions: BIIB

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

2 months ago - By: Biogen Inc. - Mentions: BIIB

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

2 months ago - By: Investor's Business Daily - Mentions: NVS BIIB

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?

2 months ago - By: Yahoo Finance - Mentions: NVS BIIB

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

2 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

2 months ago - By: Ionis Pharmaceuticals, Inc.

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

2 months ago - By: Zacks Investment Research - Mentions: ESPR

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

2 months ago - By: Yahoo Finance - Mentions: RXRX NVDA ZTS NLY ...

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today

2 months ago - By: Zacks Investment Research - Mentions: RXRX

Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?

2 months ago - By: Zacks Investment Research

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

3 months ago - By: Yahoo Finance - Mentions: HCA PANW TOL OPRX ...

Cantor Fitzgerald Upgrades HCA Healthcare, Inc.’s (HCA) Price Target, Citing Strategic Strengths

3 months ago - By: Zacks Investment Research - Mentions: AZN GSK BIIB

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

3 months ago - By: Ionis Pharmaceuticals, Inc.

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

3 months ago - By: Yahoo Finance - Mentions: JPM

Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

3 months ago - By: Yahoo Finance - Mentions: VZ AMZN AAPG KO ...

Trump’s Tariffs: 7 Things To Do Now If You’re Worried About the Unpredictable Stock Markets

3 months ago - By: Ionis Pharmaceuticals, Inc.

IONIS PHARMACEUTICALS INC (IONS) Stock News

IONS Latest News, Press Relases and Analysis

Why Morgan Stanley Upgraded This Biotech Stock to a Buy

Ionis (IONS) Q2 Revenue Soars 101%

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)

Ionis (IONS) Q2 2025 Earnings Call Transcript

Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug

Ionis reports second quarter 2025 financial results and highlights progress on key programs

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

Ionis to hold second quarter 2025 financial results webcast

Nike upgraded, Sportradar initiated: Wall Street's top analyst calls

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?

Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today

Recursion Pharmaceuticals (RXRX) Up 5.7% Since Last Earnings Report: Can It Continue?

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

Cantor Fitzgerald Upgrades HCA Healthcare, Inc.’s (HCA) Price Target, Citing Strategic Strengths

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

Ionis Pharmaceuticals, Inc. (IONS): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

Trump’s Tariffs: 7 Things To Do Now If You’re Worried About the Unpredictable Stock Markets

Ionis to host 2025 virtual Annual Meeting of Stockholders